US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma
20/03/2026 16:21
March 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb's BMY.N combination treatment for adults and adolescents aged 12 and older with previously untreated Stage III or IV classical Hodgkin's lymphoma. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber) ((siddhi.mahatole@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC